Gilead Sciences entered into a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion in implied equity value. The deal strengthens Gilead’s oncology pipeline and reinforces its leadership ambitions in cell therapy. Under the agreement, Gilead will pay $115 per share in cash at closing, along with one contingent value right (CVR) of $5 per share, tied to future sales milestones. The acquisition reflects Gilead’s strategic focus on innovative cancer immunotherapies.
Building on Existing Kite–Arcellx Collaboration
The acquisition expands an existing partnership between Arcellx and Kite Pharma, a Gilead company. Both firms have been co-developing and co-commercializing anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for patients with multiple myeloma.
Multiple myeloma remains a challenging blood cancer. Although treatment options have improved, many patients eventually relapse. As the disease progresses, therapeutic responses often diminish, toxicity increases, and viable options narrow—particularly for heavily pretreated patients. By fully integrating Arcellx, Gilead aims to accelerate development and maximize the commercial potential of anito-cel.
Anito-cel: A Potential Breakthrough in Multiple Myeloma
In clinical studies conducted to date, anito-cel has demonstrated:
*Deep and durable responses
*Predictable and manageable safety profile
*Reduced challenges associated with current CAR T-cell therapies
The Biologics License Application (BLA) for anito-cel as a fourth-line treatment for relapsed or refractory multiple myeloma is supported by:
*Phase 1 study (NCT04155749)
*Pivotal Phase 2 iMMagine1 study (NCT05396885)
The U.S. Food and Drug Administration has accepted the BLA and set a Prescription Drug User Fee Act (PDUFA) action date of December 23, 2026.
Daniel O’Day, Chairman and CEO of Gilead Sciences, stated that the agreement reflects strong confidence in anito-cel’s potential. Beyond a possible launch this year, he noted, anito-cel could evolve into a foundational therapy in multiple myeloma, including earlier lines of treatment. Furthermore, its D-domain BCMA binder may play a crucial role in advancing Gilead’s in vivo cell therapy programs.
Leveraging Arcellx’s D-Domain Technology Platform
Beyond anito-cel, Arcellx brings a proprietary D-Domain CAR technology platform, designed to generate highly specific and high-affinity target-binding domains.
This platform could support:
*Next-generation CAR T-cell therapies
*Bispecific antibody development
*In vivo cell therapy innovations
By integrating this platform, Gilead strengthens its broader oncology and inflammation portfolio while expanding its cell therapy capabilities. Rami Elghandour, Chairman and CEO of Arcellx, described the deal as a milestone for the company. He emphasized that Gilead—and particularly Kite—is well-positioned to maximize global access to anito-cel and continue advancing cell therapy leadership.
Strengthening Gilead’s Oncology and Cell Therapy Leadership
With this acquisition, Gilead accelerates its transformation into a leading oncology innovator. By combining Kite’s commercial cell therapy expertise with Arcellx’s advanced CAR T technology, the company aims to expand treatment options for patients with multiple myeloma and other cancers. As per the press release, as competition intensifies in the CAR T-cell therapy market, this strategic move positions Gilead to drive long-term growth, diversify revenue beyond legacy products, and reinforce its leadership in next-generation immunotherapies.
